fainting
HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi
A multi-national research team has discovered that two genetic factors converge to increase the risk of sudden cardiac death.
TORONTO, Ont., October 1, 2009 -- People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation using a visually-guided laser balloon catheter. The procedure was performed September 15 by Vivek Y. Reddy, MD, Professor of Medicine and Director of the Cardiac Arrhythmia Service at Mount Sinai Heart, and his colleague, Srinivas R.
Jerusalem, Sept. 14, 2009 -- A new understanding of how anesthesia and anesthesia-like states are controlled in the brain opens the door to possible new future treatments of various states of loss of consciousness, such as reversible coma, according to Hebrew University of Jerusalem scientists.
Barcelona, Spain, 1 September 2009: The REVISE Study (Reveal in the Investigation of Syncope and Epilepsy) found that 1 in 8 adult patients in the United Kingdom, previously thought to be suffering from epilepsy or in whom this diagnosis was in doubt, in fact had symptoms as a result of an abnormal pattern of heart beating, commonly found in patients with syncope (fainting).
Barcelona, Spain, 31 August: A new definition of syncope -- most commonly perceived as an episode of fainting -- makes its diagnosis more precise and now dependent on a specific cause.
PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi
Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).
The chemical bisphenol A, commonly found in many plastic household items, has been linked to yet another health problem in animals -- an increased frequency of arrhythmias, or heartbeat irregularities, a new study found. The results, seen only in females, will be presented Saturday at The Endocrine Society's 91st Annual Meeting in Washington, D.C.
A 12-year-old Dutch boy - bedridden for three years because of an inherited cardiac arrhythmia syndrome - can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.
A seemingly mild "insult" to the brain could sensitize neurons to attack by immune system proteins that are otherwise protective, researchers have found. The finding could explain why sufferers of Alzheimer's and other neurodegenerative diseases significantly worsen following such insults. The scientists believe that drugs to selectively inhibit the immune proteins could reduce the rate of neural damage in a wide range of neurodegenerative diseases. Such drugs could also protect other organs against damage from autoimmune diseases such as lupus and rheumatoid arthritis, in which the immune system attacks body tissues.
